Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs J B Hunt Transport Services Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while J B Hunt Transport Services Inc trades at $280 (market cap $26.40B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and J B Hunt Transport Services Inc pays a 0.64% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | JBHT | |
|---|---|---|
Market Cap | $39.89B | $26.40B |
Sector | Health | Industrials |
52-Week High | $491.22 | $290.07 |
52-Week Low | $278.09 | $130.65 |
Enterprise Value | $38.15B | $27.70B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
JBHT trades at $279.96, down 0.94% today, with a bullish technical outlook supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Revenue has stabilized around $12B annually, while profitability metrics show a net margin of 5.13% and ROE of 16.68%. Analyst sentiment remains positive with 57.78% buy ratings.
The stock presents a mixed valuation with elevated P/E of 43.47 but reasonable EV/EBITDA of 17.18. Near-term catalysts include Q2 earnings release on July 15, 2026. Key risks include freight market volatility and competitive pressures. The consensus price target of $273.93 suggests limited upside from current levels despite strong institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
